hydrochlorothiazide has been researched along with Metabolic Diseases in 8 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infarction." | 8.85 | Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. ( Malacco, E; Omboni, S; Parati, G, 2009) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| "Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infarction." | 4.85 | Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. ( Malacco, E; Omboni, S; Parati, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Omboni, S | 1 |
| Malacco, E | 1 |
| Parati, G | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Cooper-DeHoff, RM | 1 |
| Wen, S | 1 |
| Beitelshees, AL | 1 |
| Zineh, I | 1 |
| Gums, JG | 1 |
| Turner, ST | 1 |
| Gong, Y | 1 |
| Hall, K | 1 |
| Parekh, V | 1 |
| Chapman, AB | 1 |
| Boerwinkle, E | 1 |
| Johnson, JA | 1 |
| BOCK, HE | 1 |
| PLATT, MA | 1 |
| Kocián, J | 1 |
| Whight, C | 1 |
| Morgan, T | 1 |
| Carney, S | 1 |
| Wilson, M | 1 |
| Maebashi, M | 1 |
| Yoshinaga, K | 1 |
| Miura, K | 1 |
| Goto, K | 1 |
| Katsushima, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
1 review available for hydrochlorothiazide and Metabolic Diseases
| Article | Year |
|---|---|
Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Diuretics; Drug Therapy, Combination; Humans; H | 2009 |
1 trial available for hydrochlorothiazide and Metabolic Diseases
| Article | Year |
|---|---|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
6 other studies available for hydrochlorothiazide and Metabolic Diseases
| Article | Year |
|---|---|
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
[PROGRESS IN PRACTICAL MEDICINE FROM THE VIEWPOINT OF THE INTERNIST].
Topics: Anemia; Anemia, Hemolytic; Anti-Bacterial Agents; Arthritis; Arthritis, Rheumatoid; Clinical Enzyme | 1963 |
CARDIAC AND METABOLIC DISEASE, AND INFECTIONS IN THE OBSTETRIC PATIENT.
Topics: Acetazolamide; Acid-Base Equilibrium; Blood Circulation; Chlorothiazide; Chlorthalidone; Diet, Sodiu | 1964 |
[Idiopathic hypercalciuria--its pitfalls and therapy].
Topics: Adult; Aged; Calcium; Female; Humans; Hydrochlorothiazide; Male; Metabolic Diseases; Middle Aged | 1978 |
Diuretics, cardiac failure and potassium depletion: a rational approach.
Topics: Aged; Amiloride; Body Weight; Diet, Sodium-Restricted; Diuretics; Edema; Furosemide; Heart Failure; | 1974 |
Suppressed plasma renin activity in in hypertensive patients--its evaluation for the diagnosis of primary aldosteronism.
Topics: Aldosterone; Cushing Syndrome; Diet, Sodium-Restricted; Glomerulonephritis; Humans; Hydrochlorothiaz | 1969 |